Market research on the consumer health industry. Our reports feat...
Market research on the consumer health industry. Our reports feature a wealth of standardised and cross-comparable statistics including total market sizes, market share and share data, distribution and industry trends.
In 2024, analgesics is expected to continue to show stable growth in retail current value terms in Vietnam, due to the growing popularity of self-medication. Vietnamese consumers are turning to analgesics for relief from mild pain caused by…
The consistent value growth recorded by analgesics in the UK over the review period is rationalising in 2024, increasing by 6% compared to a stronger performance by the category in the previous two years. Local consumers are looking to preventative…
Value sales of analgesics in the United Arab Emirates continue to rise, with local consumers increasingly using analgesics to treat more than just conventional headaches or joint pain. In 2024, Panadol (GSK Consumer Healthcare) launched an…
Demand for analgesics in the Philippines is expected to continue growing in 2024, driven by an expanding consumer base as more Filipinos become aware of the benefits of using these products for headaches relief from other types of moderate pain.…
Demand for analgesics in Thailand, for both adult and paediatric segments, continues to rise in 2024. Although the main sales driver of analgesics tends to be domestic consumption, demand among inbound tourists, particularly with regard to medicines…
Analgesics is set to see slow retail current value growth in New Zealand in 2024. During the period 2020-2021, the government’s response to the COVID-19 pandemic included movement restrictions and reduced levels of social interaction, which meant…
Analgesics remains an important category within the consumer health industry in Mexico. However, after a peak of retail current value growth for several years during the pandemic, the category returned to a more normal rate of increase in 2023, and…
Although systemic analgesics in Japan is not set to see significant growth in retail current value terms in 2024, as it did in 2023, it is expected to continue to increase. A major event that impacted Japan in May 2023 was the reclassification of…
Analgesics is set to see a decline in retail value sales in current terms in Italy in 2024. The category’s performance was adversely affected by a peculiar flu season. Despite the record 14.5 million infections reported by RespiVirNet, the flu season…
Analgesics in Hong Kong remains on its path of recovery as the resumption of travel has led to an increase in retail tourism activity. Historically, tourist expenditure, particularly from mainland Chinese consumers, represented a substantial source…
Systemic analgesics, represented mainly by ibuprofen, witnessed an extraordinary surge in demand in China during the first and second quarters of 2023. This unprecedented growth was a direct consequence of the lifting of lockdown restrictions in the…
Sales of analgesics in Chile, in both retail volume and value terms, declined in 2023, primarily due to high comparative rates from previous years when demand was heavily influenced by their widespread use to alleviate vaccination-related symptoms.…
Overall, analgesics in Belgium, the largest OTC category, is projected to see stable retail current value sales over 2024 amid inflationary pressure. Beside the stability in retail value terms, retail volume sales of analgesics in Belgium is…
Analgesics witnessed phenomenal current value growth in 2024 as rampant inflation in Argentina pushed up costs and led to strong price increases. In the face of narrowing profit margins, players were forced to increase prices to cover higher…
Analgesics in the US is expected to see a slight decline in retail current value terms in 2024. This performance is largely being led by mid-single digit slowdowns for systemic paediatric analgesics, sales of which are still rebounding from the high…
Within analgesics in France, OTC analgesics is recording underwhelming growth in 2024, attributable to several factors. For example, 2023-2024 has been seeing lower incidence of flu and common colds compared to 2022, and for a shorter period between…
Sales of analgesics are declining in current value and retail volume terms in 2024. One of the reasons for this trend is the decline in purchasing power in Azerbaijan with the rising price of basic goods and services putting a strain on consumers’…
Demand for analgesics in Algeria continues to grow steadily in 2024, albeit at a slower pace, with consumer preferences largely limited to acetaminophen, aspirin, and combination products. Most Algerians use analgesics only on an occasional basis.…
Analgesics is set to maintain steady current value growth in Brazil in 2023, and will remain the largest category within OTC, with a 40% share of value sales. The consumption of analgesics is mainly related to general pain, fever, and the relief of…
Consumers are increasingly embracing self-medication, especially for minor illnesses, and this contributed to modest growth in 2023, as well as continuing population growth. Analgesics have achieved a substantial penetration rate in Cameroon,…